ABOS — Acumen Pharmaceuticals, Inc.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2021-07-01.
Performance
Technicals
Others in Healthcare
Measured signals that fired on ABOS
| date | signal | measured base rate |
|---|---|---|
| 2026-03-16 | Equal highs taken out structure | -0.70% over 21 days · t = -8.28 · n = 68,636 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-06-17 | Porter Derrell Director | Open-market sale | 13.0K | 2.33 | 30.3K |
| 2026-06-17 | Porter Derrell Director | Option exercise | 13.0K | 1.07 | 14.0K |
| 2026-06-16 | Porter Derrell Director | Open-market sale | 12.8K | 2.33 | 29.8K |
| 2026-06-15 | Porter Derrell Director | Open-market sale | 6.5K | 2.35 | 15.1K |
| 2026-06-15 | Porter Derrell Director | Option exercise | 6.5K | 1.07 | 6.9K |
| 2026-06-09 | Fountain Nathan B Director | Open-market sale | 6.4K | 2.23 | 14.3K |
| 2026-06-03 | Shah Rajeev M. Director | Grant or award | 35.5K | 0.00 | 0 |
| 2026-06-03 | Kolchinsky Peter Director | Grant or award | 35.5K | 0.00 | 0 |
| 2026-06-03 | RA CAPITAL MANAGEMENT, L.P. Director | Grant or award | 35.5K | 0.00 | 0 |
| 2026-06-03 | RA Capital Healthcare Fund LP Director | Grant or award | 35.5K | 0.00 | 0 |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 49.5M | 21.0M |
| Sands Capital Alternatives, LLC | 8.8M | 3.7M |
| Alyeska Investment Group, L.P. | 5.8M | 2.5M |
| FRANKLIN RESOURCES INC | 5.4M | 2.3M |
| ADAR1 Capital Management, LLC | 5.1M | 2.2M |
| Knollwood Investment Advisory, LLC | 3.8M | 1.6M |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.6M | 1.5M |
| FMR LLC | 2.7M | 1.2M |
| Ikarian Capital, LLC | 2.5M | 1.1M |
| Hudson Bay Capital Management LP | 2.3M | 968.9K |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Latest SEC filings
| form | filed | period | |
|---|---|---|---|
| S-8 | 2026-08-12 | — | on EDGAR ↗ |
| 10-Q | 2026-08-12 | 2026-06-30 | on EDGAR ↗ |
| 8-K | 2026-08-12 | 2026-08-12 | on EDGAR ↗ |
| 4 | 2026-06-17 | 2026-06-15 | on EDGAR ↗ |
| 144 | 2026-06-17 | — | on EDGAR ↗ |
| 144 | 2026-06-16 | — | on EDGAR ↗ |
| 8-K | 2026-06-16 | 2026-06-12 | on EDGAR ↗ |
| 144 | 2026-06-15 | — | on EDGAR ↗ |
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- Acumen Pharmaceuticals, Inc. (ABOS) filed form 8-K · 2026-08-12 · SEC EDGAR
Ask the AI about ABOS
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →